Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "2020"

617 News Found

AstraZeneca Pharma India PAT at Rs 10.24 crores
Biotech | August 09, 2021

AstraZeneca Pharma India PAT at Rs 10.24 crores

Board declares interim dividend of Rs 2 per equity share

Alkem Laboratories PAT at Rs 468.12 crore for Q1FY22
News | August 08, 2021

Alkem Laboratories PAT at Rs 468.12 crore for Q1FY22

EPS stood at Rs 39.15

Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22
Healthcare | August 08, 2021

Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22

Board approves fundraise of Rs 1500 crore

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US

Abbott India net profit rises to 8.5 per cent in Q1FY22
News | August 08, 2021

Abbott India net profit rises to 8.5 per cent in Q1FY22

PAT rises to Rs 195.76 crore

Cipla posts net profit at Rs 715 crores
News | August 08, 2021

Cipla posts net profit at Rs 715 crores

India business contributes to a stellar performance

Divi's Labs posts a 13 per cent rise in PAT at Rs 557.11 crore
News | August 08, 2021

Divi's Labs posts a 13 per cent rise in PAT at Rs 557.11 crore

Forex gains stood at Rs 20 crore for the quarter

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.

Sanofi to acquire Translate Bio
Biotech | August 07, 2021

Sanofi to acquire Translate Bio

Advances deployment of mRNA technology across vaccines and therapeutics development

Lyka Labs reports improved set of numbers in Q1FY22
News | August 05, 2021

Lyka Labs reports improved set of numbers in Q1FY22

The company has been consistently reducing debt

Latest Stories

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging